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Age-related macular degeneration (AMD) is one retinal aging process that may lead to
irreversible vision loss in the elderly. Its pathogenesis remains unclear, but oxidative stress
inducing retinal pigment epithelial (RPE) cells damage is perhaps responsible for the aging
sequence of retina and may play an important role in macular degeneration. In this study,
we have reprogrammed T cells from patients with dry type AMD into induced pluripotent
stem cells (iPSCs) via integration-free episomal vectors and differentiated them into RPE
cells that were used as an expandable platform for investigating pathogenesis of the
AMD and in-vitro drug screening. These patient-derived RPEs with the AMD-associated
background (AMD-RPEs) exhibited reduced antioxidant ability, compared with normal
RPE cells. Among several screened candidate drugs, curcumin caused most significant
reduction of ROS in AMD-RPEs. Pre-treatment of curcumin protected these AMD-RPEs
from H2O2-induced cell death and also increased the cytoprotective effect against the
oxidative stress of H2O2 through the reduction of ROS levels. In addition, curcumin
with its versatile activities modulated the expression of many oxidative stress-regulating
genes such as PDGF, VEGF, IGFBP-2, HO1, SOD2, and GPX1. Our findings indicated
that the RPE cells derived from AMD patients have decreased antioxidative defense,
making RPE cells more susceptible to oxidative damage and thereby leading to AMD
formation. Curcumin represented an ideal drug that can effectively restore the neuronal
functions in AMD patient-derived RPE cells, rendering this drug an effective option
for macular degeneration therapy and an agent against aging-associated oxidative
stress.
Keywords: oxidative stress, age-related macular degeneration, patient-specific induced pluripotent stem cells,
retinal pigment epithelial, antioxidant, curcumin
INTRODUCTION
Retinal degeneration is one of the common sequelae of aging,
among which age-related macular degeneration (AMD) has
become a leading cause of irreversible blindness worldwide
(Friedman et al., 2004; Song and Dunaief, 2013). According to
clinical presentation and ancillary examinations, AMD is fur-
ther subdivided into wet and dry type (Landa et al., 2011). The
slowly progressing and more frequent dry AMD is character-
ized by the presence of an irregular area of depigmentation as
a result of the loss of retinal pigment epithelial (RPE) cells, and
causes gradual geographic atrophy of the retina (Bowes Rickman
et al., 2013). The well-established risk factors associated with
AMD are advanced age, diet intake, cigarette smoking, and racial
variety (Nowak, 2006; Tokarz et al., 2013). The complement
factor H gene (CFH) and 10q26 containing age-related macu-
lopathy susceptibility protein 2 (ARMS2, also called LOC387715)
also be related to patients’ susceptibility to macular inflamma-
tion (Fritsche et al., 2010; Macdonald and Miller, 2011). There
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is no effective drug or strategy to improve this debilitating visual
disease. Therefore, development of novel therapies for AMD is
urgently needed.
The pathogenesis of AMD remains unclear, but oxidative stress
and the production of reactive oxygen species (ROS) are per-
haps responsible for the aging sequence of retina and may play
an important role in the pathogenesis of macular degeneration
(Blasiak et al., 2014). Oxidative stress can affect both the lipid
rich retinal outer segment structure and the light processing in
the macula. The response to oxidative stress involves several cellu-
lar defense reactions such as increases in antioxidant production
and proteolysis of damaged proteins (Winkler et al., 1999). The
imbalance between production of damaged cellular components
and degradation leads to the accumulation of detrimental prod-
ucts, for example, intracellular lipofuscin and extracellular drusen
(Tate et al., 1995). RPE cells are particularly susceptible because
of light illumination, high oxygen tension, accumulation of lipid
molecules, and other types of stress (Beatty et al., 2000). On
the other hand, anti-oxidative enzymes in RPE cells decrease
with age, potentially allowing ROS to cause DNA damage and
ultimately leading to the apoptosis of RPE cells (Samiec et al.,
1998). Although it has been accepted that the RPE is the major
pathogenic target of macular degeneration, obtaining a sufficient
number of RPE cells from suitable donors for drug screening and
disease modeling remains an obstacle.
Human induced pluripotent stem cells (iPSCs) technology had
been successfully generated via the retrovirus-mediated transfec-
tion of four transcription factors (Oct4, Sox2, Klf-4, and c-Myc)
(Takahashi et al., 2007; Yu et al., 2007). Several studies had been
made to generate iPSCs from patients with various diseases pro-
viding new opportunities for regenerative medicine and in vitro
disease modeling (Dimos et al., 2008; Park et al., 2008; Maehr
et al., 2009). Among disease, those involving retina are necessary
and urgent to consider for iPSCsmodeling, because of these tissue
are not amenable to routine biopsy. In the previous study reported
by Osakada et al., human iPSCs were capable of differentiation
into differentiated retinal progenitors, RPE cells, and photorecep-
tors (Osakada et al., 2009). Singh et al. recently also generated
Best disease patient-specific iPSCs and differentiated these cells
into RPE-like cells and viewed this technique as a great model of
degenerative retinal disorder (Singh et al., 2013). Indeed, RPE is
one of a few cell types derived from human iPSCs that have met
standards for use in human clinical trials (Schwartz et al., 2012).
In this study, we isolated T cell from peripheral blood instead of
fibroblasts from skin to generate AMD patient-specific induced
pluripotent stem cells (AMD-iPSCs). In addition, we used non-
integration Episomal vectors instead of integrating viral vectors
to reduce the risk of transgenic sequences inserted into the target
cell genome. We then differentiated these AMD-iPSCs into RPE-
like cells (AMD-RPEs) that were used as an expandable platform
for in vitro drug screening for investigating the candidate drug
that can reduce ROS production and protect RPE cells in AMD.
Curcumin is a natural plant extract from Curcuma longa L
and widely used in traditional Chinese medicine and in the food
industry (Ammon and Wahl, 1991). Curcumin had been demon-
strated several types of biological and pharmacological activities,
including anti-diabetes, anti-carcinogenic, anti-tumor invasion,
anti-angiogenesis activities, anti-oxidant, and anti-inflammation
(Aggarwal and Harikumar, 2009; Noorafshan and Ashkani-
Esfahani, 2013). In addition, curcumin had been shown to have
the possibility of slowing the progress of macular degeneration
by protecting RPE cells from light- and oxidant stress- induced
cell death and promoting the trafficking of accumulated pro-
teins in retinal cells (Mandal et al., 2009; Woo et al., 2012). In
this study, via the AMD patient-specific iPSCs drug screening
platform we demonstrated that curcumin serves as an effective
scavenger of ROS and enhances the synthesis of antioxidative
enzymes in dry AMD iPSC-derived RPE cells. Moreover, pre-
treatment of curcumin protected these AMD-related RPE cells
from H2O2-induced cell death. This study suggested that iPSCs
were a useful for purposes of personalized medicine. Our results
of drug selection using iPSC-derived RPE cells may show us an
alternative way to delay oxidative RPE cell death and help prevent
the exacerbation of macular degeneration.
MATERIALS AND METHODS
T CELL ACTIVATION AND EXPANSION
This research followed the tenets of the Declaration of Helsinki,
and protocols for this study were approved by the by the Internal
Research Board of Taipei Veterans General Hospital (Board No.
2013-11-012B). All samples were obtained after patients had
given informed consent. PBMC was isolated from five patients
with dry AMD and two unaffected control using Ficoll-Plaque
Plus (Amersham Biosciences) according to the manufacturer’s
protocol. The characteristics of 5 patients with AMD were
summarized in Figure 1C. In brief, one ratio of blood sample
was layered on one ratio of Ficoll-Plaque Plus, pellet (400 ×
g, 30min at 20◦C) and the buffy coat was collected, washed
twice with PBS and cultured in DMEM (Sigma) (100 IU/mL
of penicillin, 100μg/mL of streptomycin [Flowlab] and 10%
v/v Fetal Bovine Serum [FBS] [PAA, Austria]). T cells were
expanded in freshly prepared AIM-V Medium (Invitrogen) sup-
plemented with pen/strep/glutamine (Invitrogen) plus 300 IU/ml
rhIL2 (Peprotech) and 10 ng/ml soluble anti-CD3 antibody
(eBioscience, OKT3 clone) (Berger et al., 2003).
HUMAN iPSCs GENERATION AND CULTURE
To generate integration-free iPSCs, cells were nucleofected with
3μg expression plasmid mixture using Amaxa™ human T
Cell Nucleofector™ Kit (Lonza). In each nucleofection, 0.83μg
PCXLE-hOCT3/4-shp53, 0.83μg PCXLE-hSK, 0.83μg pCXLE-
hUL, and 0.5μg pCXWB-EBNA1 were used. 2 × 106 cells were
nucleofected with Amaxa Nucleofector II using program V-024.
Cells were cultured the exactly same way as for reprogramming
with lentiviral vector expect that every 10–14 days, freshly thawed
inactivated mouse embryonic fibroblasts (MEFs) feeder cells were
added into each well. The number of ALP-positive iPSC colonies
was counted at 3–4 weeks after nucleofection. Undifferentiated
iPSCs were maintained on inactivated MEFs (50,000 cells/cm2)
in human ESC medium (DMEM/F12 (Gibco) supplemented
with 20% KnockOut serum replacer (KSR; Invitrogen), 0.1mM
non-essential amino acids (Invitrogen), 1mM L-glutamine,
0.1mM ß-mercaptoethanol, 10 ng/ml recombinant human basic
fibroblast growth factor (bFGF), and antibiotics (Gibco). To
Frontiers in Aging Neuroscience www.frontiersin.org August 2014 | Volume 6 | Article 191 | 2
Chang et al. AMD iPSC-derived RPEs for drug screening
FIGURE 1 | Imaging findings and characteristics of patients with
dry AMD. (A) Color fundus and optical coherence tomography scans
of patient with intermediate dry AMD. Upper left: yellowish
depositions, drusen, were detected by color fundi photograph. Upper
right: magnified picture of posterior pole revealed drusen locating
temperol and adjacent to macular regions. Lower: optical coherence
tomography images across the fovea showed small drusenoid
depostions. (B) Color fundal picture and optical coherence tomography
scans of patient with advanced dry AMD. Upper left: Extensive
intermediate to large drusen were detected by color fundal
photograph. Upper right: magnified pictures of macula revealed
extensive drusen all over posterior pole. Lower: optical coherence
tomography images across the fovea showed elevated drusenoid
depostions with RPE irregularities. (C) Demographic information of
iPSC cell lines generated from peripheral blood cells of patients with
intermediate and advanced dry AMD.
prevent cell contamination by MEFs, these iPSCs were trans-
ferred to feeder-free/serum-free culture in HESF V2 medium
(Cell Science & Technology) without KSR supplementation as
described previously (Chien et al., 2012).
DIFFERENTIATION FOR RETINAL PIGMENT EPITHELIAL CELLS
The iPSCs were differentiated to RPE according to the pro-
tocol established by Dr. Osakada (Osakada et al., 2009). The
iPSCs clumps were first incubated in human ES cell cul-
ture medium supplemented with 10μM Y-27632 (WAKO),
5μM SB431542 (Sigma–Aldrich) and 3μM CKI-7 (Sigma–
Aldrich) for 1 day. The cells were incubated in a dif-
ferentiation medium (Glasgow minimum essential medium
[GMEM; Invitrogen], 1mM sodium pyruvate, 0.1mM non-
essential amino acids, and 0.1mM 2-mercaptoethanol) contain-
ing 20% knockout serum replacement (KSR; Invitrogen) for
4 days, then in 15% KSR-containing differentiation medium
for 6 days, and finally in 10% KSR-containing differentiation
medium for 11–40 days. Y-27632 (10μM), SB431542 (5μM)
and CKI-7 (3μM) were added to the differentiation medium
for the first 13 and 19 days, respectively. Partially differen-
tiated cells were dissociated and incubated on non-adhesive
dishes (Corning) in RPE maintenance medium (DMEM:F12
[7:3] supplemented with B-27 supplement [Invitrogen] and
2mM l-glutamine [Invitrogen]) for 10 days. The resulting
RPE cell aggregates were isolated and replated on CELLstart-
(Invitrogen) coated dishes in RPE maintenance medium sup-
plemented with 0.5μM SB431542 and 10 ng/ml bFGF. The
medium was changed every 2–3 days. Thereafter, RPE cells
formed compact monolayers and re-pigment, typically 90–120
days.
ALKALINE PHOSPHATASE ASSAY
The cells were fixed with 4% paraformaldehyde and washed with
PBST. The alkaline phosphatase activity was determined by the
Alkaline Phosphatase Substrate Kit III (Vector Labs) following the
manufacturer’s protocol. Colonies stained red indicated positive
alkaline phosphatase activity.
REVERSE TRANSCRIPTION-POLYMERASE CHAIN REACTION (RT-PCR)
Total RNA was isolated with TRIzol Reagent (Invitrogen) and
quantified by spectrophotometry at 260 nm. On a GeneAmp®
PCR System 9700 thermocycler (Applied Biosystems), 5μg
of each total RNA was reverse-transcribed with SuperScript
III (Invitrogen) at 55◦C for 1 h into total complementary
DNA, which was then used as the template for the subse-
quent PCR reactions and analysis. The PCR reactions involved
an initial denaturation at 94◦C for 5min, followed by 25
or 30 cycles at 94◦C for 30 s, exposure to an appropriate
annealing temperature (58–62◦C) for 30 s, and then a final
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incubation at 72◦C for 45 s. The primers and cycling condi-
tions for real-time RT-PCR were shown as Table 1. Amplified
RT-PCR products were then analyzed on 1% agarose gels
and visualized using ethidium bromide staining and a cam-
era system (Transilluminator/SPOT; Diagnostic Instruments).
The gel images of the RT–PCR products were directly
scanned (ONEDscan 1-D Gel Analysis Software; Scanalytic
Inc.), and the relative densities were obtained by determin-
ing the ratio of the signal intensity to the GAPDH or β-actin
band.
IMMUNOFLUORESCENCE STAINING
The living cells and spheres were fixed in 4% paraformaldehyde,
permeabilized in 0.1% Triton X-100, and blocked in 5% normal
goat serum-PBS. Cells were incubated with primary antibodies,
and the antibody and conditions were shown as Table 2. After
being washed three times in PBS, the cells were then incubated
with goat anti-mouse or secondary antibodies conjugated with
FITC (green) or PE (red). DAPI was used as nuclear stain (blue).
Images were obtained using fluorescent microscopy and a digital
camera.
QUANTITATIVE RT-PCR
The total RNA (5μg) of each sample was reversely transcribed
in 20mL using 0.5mg of oligo dT and 200U Superscript II RT
(Invitrogen). The amplification was carried out in a total vol-
ume of 20ml containing 0.5mM of each primer, 4mM MgCl2,
2ml LightCycler FastStart DNA Master SYBR green I (Roche
Diagnostics) and 2ml of 1:10 diluted cDNA. The quantification
of the unknown samples was performed by LightCycler Relative
Quantification Software, version 3.3 (Roche Diagnostics). PCR
reactions were prepared in duplicate and heated to 95◦C for
10min followed by 40 cycles of denaturation at 95◦C for 10 s,
annealing at 55◦C for 5 s, and extension at 72◦C for 20 s. All PCR
reactions were performed in duplicate. Standard curves (cycle
threshold values versus template concentration) were prepared
for each target gene and for the endogenous reference (GAPDH)
in each sample. The primers for quantitative real-time RT-PCR
were shown as Table 3.
INTRACELLULAR REACTIVE OXYGEN SPECIES (ROS) PRODUCTION
The measurement of intracellular ROS production by the probe
20, 70-dichlorofluorescein diacetate (DCFH-DA; Molecular
Table 2 | List of proteins tested by antibodies.
Protein Assay Origin Dilution Incubation period
Oct-3/4 IF Cell signaling #2840 1:200 4◦C Overnight
NANOG IF Cell signaling #3580 1:500 4◦C Overnight
Tira-1-60 IF Cell signaling #4746 1:800 4◦C Overnight
Tira-1-81 IF Cell signaling #4745 1:800 4◦C Overnight
Nestin IF CHEMICON AB5922 1:200 4◦C Overnight
AFP IF Cell signaling #3903 1:200 4◦C Overnight
SMA IF Millipore #04-1094 1:200 4◦C Overnight
ZO1 IF Zymed 61-7300 1:200 RT 1h
RPE65 IF Abcam ab13826 1:200 RT 1h
p-JNK WB Invitrogen 36-9300 1:2000 4◦C Overnight
JNK WB Cell signaling #9258 1:2000 4◦C Overnight
GAPDH WB GeneTex GTX100118 1:10000 4◦C Overnight
Abbreviations: WB, Western blot; IF, immunofluorescence; RT, room
temperature.
Table 3 | The sequences for the primers of quantitative real time
RT-PCR.
Gene Forward primer Reverse primer
GAPDH CAGAACATCATCCCTGCCTCTAC TTGAAGTCAGAGGAGACCACCTG
SOD2 GGGGTGCTGGTTTGCGTCGT GACCTGCACTGGTACAGCCTGC
GPX1 TGGGCATCAGGAGAACGCCA GCGTAGGGGCACACCGTCAG
HO-1 TCATGAGGAACTTTCAGAAGGGCC TCTCCTTGTTGCGCTCAATCTCCT
VEGF AGCACATAGGAGAGATGAGCTTCC ACGTCTGCGGATCTTGTACAAAC
FDGF TGTTCCAGATCTCGCGGAAC GCGGCCACACCAGGAAG
IGFBP-2 GCGCGGGTACCTGTGAAA CTACTGCTGGTGAGACTCCCT
Table 1 | The sequences for the primers of RT-PCR.
Gene Forward primer Reverse primer
endo Oct4 GACAGGGGGAGGGGAGGAGCTAGG CTTCCCTCCACCCAGTTGCCCCAAAC
endo Sox2 GGGAAATGGGAGGGGTGCAAAAGAGG TTGCGTGAGTGTGGATGGGATTGGTG
endo Klf4 ACGATCGTGGCCCCGGAAAAGGACC TGATTGTAGTGCTTTCTGGCTGGGCTCC
endo c-Myc GCGTCCTGGGAAGGGAGATCCGGAGC TTGAGGGGCATCGTCGCGGGAGGCTG
Nanog CAGCCCCGATTCTTCCACCAGTCCC CGGAAGATTCCCAGTCGGGTTCACC
REX CAGATCCTAAACAGCTCGCAGAAT GCGTACGCAAATTAAAGTCCAGA
DPPA2 CCGTCCCCGCAATCTCCTTCCATC ATGATGCCAACATGGCTCCCGGTG
GDF3 CTTATGCTACGTAAAGGAGCTGGG GTGCCAACCCAGGTCCCGGAAGTT
RLBP1 GCCATGGTACTTCACCACGA GGCTCCTTGCCTGTTTTCAC
RPE65 ACCCAGTGGGGGAAGATTAC GCAGCAGAGATCCACAATCA
MITF ACCATCAGCAACTCCTGTCC CCAGTTCCGAGGTTGTTGTT
PAX6 GAGGTCAGGCTTCGCTAATG CTCACACATCCGTTGGACAC
β-Actin GCATTGCTTTCGTGTAAATTATGT ACCAAAAGCCTTCATACATCTCA
GAPDH GTCGCCAGCCGAGCCACATC CCAGGCGCCCAATACGACCA
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Probes) was mentioned previously (Woo et al., 2012). In
brief, cells were incubated with 5mmol/L DCFH-DA in culture
medium for 30min at 37◦C, followed by washing with PBS and
flow cytometry analysis.
MTT ASSAY
For evaluation of cell survival, cells were seeded on 24-well
plates at a density of 2 × 104 cells/well, followed by the addi-
tion of methyl thiazol tetrazolium (MTT; Sigma) at the end of
cell culture. The amount of MTT formazan product was deter-
mined using a microplate reader at an absorbance of 560 nm
(SpectraMax 250, Molecular Devices).
ENZYME-LINKED IMMUNOSORBENT ASSAY (ELISA)
After 3 days of RPE cells incubation, culture media was collected
and measured for PDGF-BB (Abcam; ab100624), VEFG (Abcam;
ab100663) and IGFBP-2 (Abcam; ab100540) levels using human
ELISA kit)according to the manufacturer’s protocol. The opti-
cal densities were determined within 30min and recorded with
a microplate reader (BioTek, EXL800, Winooski, VT) at 450 nm.
WESTERN BLOT ASSAY
Whole cell lysates were separated by electrophoresis on 12% SDS–
PAGE and transferred to polyvinylidene fluoride membrane. The
membranes were blocked with 5% nonfat milk at room tempera-
ture for 1 h. The primary antibodies in TBST buffer containing
3% nonfat milk at 4◦C overnight and subsequently with sec-
ondary antibody conjugated with peroxidase at 25◦C for 1 h.
The immunoblots were developed using an enhanced chemilu-
minescence system, and the luminescence was visualized on X-ray
film. The antibodies for western blot are shown as supplementary
Table 2.
STATISTICAL ANALYSIS
The results were expressed as the mean ± SD. Statistical anal-
yses were performed using the t-test for comparing 2 groups,
and one-way ANOVA was used to detect differences among 3 or
more groups. The results were considered statistically significant
at P < 0.05.
RESULTS
CLINICAL FINDINGS OF DRY TYPE AGE-RELATED MACULAR
DEGENERATION
Numerous studies have focused on human iPSCs as a result
of their ability to generate infinitely and maintain the ability
to differentiate into various cell types (Takahashi et al., 2007).
In this study, we isolated T cell from dry type AMD patients
to generate patient-specific iPSCs and then differentiated these
FIGURE 2 | Generation and characterization of iPSCs derived from
patients with AMD and unaffected control. (A) Schematic diagram of the
reprogramming with episomal plasmids via electroporation.
(B) Phase-contrast photomicrograph and alkaline phosphatase activity of
undifferentiated control iPSCs (Ctrl-iPSCs) and AMD iPSCs (AMD-iPSCs).
Scale bar = 100μm. (C) Immunofluorescence staining demonstrated the
expression of pluripotency markers (OCT4, TRA-1-61, NANOG, and TRA-1-81)
in undifferentiated iPSCs from patients and unaffected. Nuclei were
counterstained with DAPI (blue). Scale bar = 30μm. (D) The RT–PCR results
indicated an ESC-like gene expression pattern in representative colonies of
iPSCs. T cells were used as a negative control, and human ES H9 cells were
used as a positive control.
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iPSCs into RPE-like cells that were used as an expandable plat-
form for in vitro drug screening. We obtained 20ml peripheral
blood from the donors (including five patients with dry AMD and
two unaffected control). Based on age-related eye disease study
(AREDS) staging, we divided these cases into intermediate and
advanced dry AMD. Intermediate dry AMD is defined as at least
one eye expressing one ormore intermediate drusen (63∼124μm
in diameter), extensive small drusen, or pigment abnormalities
associated with AMD. Advanced dry AMD is defined as at least
one eye having one or more large drusen (>125μm in diame-
ter) or extensive intermediate drusen. Color fundi photographs of
intermediate dry AMD showed the presence of numerous small
to intermediate drusen, deposited primarily between the tem-
poral and macula regions. Horizontal 6-mm optical coherence
tomography scans revealed AMD retinas with drusenoid deposi-
tions in the macular area (Figure 1A). In the cases with advanced
dry AMD, color fundi pictures revealed extensive intermediate
to large drusen in macula and the posterior pole. Horizontal 6-
mm optical coherence tomography scans revealed AMD retinas
with macular depositions and RPE irregularities (Figure 1B). The
demographic data in these 5 cases are summarized in Figure 1C.
The patients were aged from 69–86-years-old. iPS cell lines
were achieved successfully in all 5 cases with subsequent RPE
differentiation.
GENERATION OF iPSCs AND RPEs FROM AMD PATIENTS
AMD results from RPE dysfunction or loss associated with
photoreceptor fallout, Bruch’s membrane thickening, and
choriocapillary hypoperfusion (Young, 1987). However,
obtaining a number of suitable RPE cells for in vitro study is still a
problem. Although fibroblasts from skin biopsy or other sources
(such as dental pulp cells) were used in many studies for the gen-
eration of iPSCs, peripheral blood mononuclear cells (PBMCs)
have been widely accepted as a more convenient and an almost
unlimited resource for cell reprogramming (Staerk et al., 2010;
Seki et al., 2012). In this study, we used EBNA1-based episomal
vectors, a non-viral system that can reprogram somatic cells into
iPSCs in both feeder-dependent and feeder-free conditions, to
generated iPSCs from T cells via electroporation (Figure 2A).
These integration-free iPSCs have the capability to be utilized
for a broad range of applications, including pre-clinical research
and human gene therapy, thus further delivering on the promise
of iPSCs. These reprogrammed cells progressively formed
colonies with increasing size during the reprogramming process.
These colonies were stained positive for alkaline phosphate
(ALP), and exhibited morphology indistinguishable from that
of human ESCs (Figure 2B). As shown by immunofluorescence,
selected clones exhibited the stamens signature and revealed
the strong expression of Oct4, Nanog, Tra1-60, and Tra1-81
in the 20th-passage iPSCs (Figure 2C). RT-PCR also showed
that both Ctrl- and AMD-iPSCs expressed various stemness
genes, such as Oct4, Sox2, klf4, Nanog, REX, DPPA2, and GDF3,
identical to those observed in H9 human ESC lines (Figure 2D).
Using differentiation protocols for tridermal lineages, both the
20th-passage Ctrl-iPSC-derived embryoid bodies (EBs) and
AMD-iPSC-derived EBs could be induced to differentiate into
FIGURE 3 | Differentiation of induced pluripotent stem cells into retinal
pigment epithelial cells. (A) Schematic diagram of the culture procedure for
RPE differentiation. (B) Light microscopic images of RPE cells derived from
control and AMD iPSCs confirmed characteristic RPE morphology and
pigmentation. Scale bars = 20μm. (C) RT–PCR analysis revealed the
expression of characteristic RPE genes. (D) Immunofluorescence staining for
ZO-1 and RPE65 demonstrated morphology and tight junction formation in
Ctrl-RPEs compared with AMD-RPEs.
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FIGURE 4 | Accumulation of endogenous ROS in AMD-RPEs as a
drug screening platform. (A) Endogenous and H2O2-induced ROS
were measured with flow cytometry. In H2O2-induced ROS group,
RPE cells were separately pretreated with 200μM H2O2 for 6 h. Each
bar represents the mean ± SD of three independent experiments
(∗p < 0.05, compared with ctrl-RPE). (B) Endogenous ROS were
measured by flow cytometry after treatment with dietary supplements
for retinal protection and natural compounds for anti-oxidative stress
for 24 h (10μM β-carotene, 10μM retinoic acid, 5μM forskolin,
200μM isoproterenol, 10μM resveratrol, 10μM vitamin C, 10μM
curcumin, and 20μM Q10). Each bar represents the mean ± SD of
three independent experiments (∗p < 0.05, compared with non-treated
control).
neuron-like cells, smooth muscle cells, and hepatocyte-like cells
(ectoderm, mesoderm, and endoderm) (data not shown). These
results demonstrated that AMD patient-derived iPSCs exhibited
pluripotent properties and capabilities of multi-lineage differen-
tiation. We further employed the culture protocol described by
Osakada et al., with brief modifications, for RPE differentiation
(Osakada et al., 2009). We used patient-specific iPSC-derived
RPE cells to model the pathophysiological features of macular
degeneration (Figure 3A). Using this protocol, both Ctrl- and
AMD-iPSCs underwent RPE-specific morphological changes and
pigmentation and differentiated into RPE-like cells (Figure 3B).
RT-PCR confirmed the expression of several RPE-specific
markers, including RLBP1, RPE65, MITF, and PAX6, in both
Ctrl-RPEs and BD-RPEs (Figure 3C). Immunofluorescence
assays indicated that AMD-RPEs exhibited significantly lower
ZO-1 and RPE65 expression than Ctrl-RPEs, suggesting tight-
junction in AMD-RPEs were defective (Figure 3D). These data
demonstrated that both Ctrl- and AMD-iPSCs were competent to
differentiate into pigment cells with typical RPE characteristics.
iPSC-DERIVED RPEs AS A DRUG SCREENING PLATFORM OF MACULAR
DEGENERATION
The RPE is a monolayer of pigmented cells forming part of
the blood retina barrier and is particularly susceptible to oxida-
tive stress because of the layer’s high consumption of oxygen.
Thus, chronic oxidative stress induces RPE damage that is respon-
sible for the aging process and plays a significant role in the
pathogenesis of AMD (Beatty et al., 2000; Yildirim et al., 2011).
Our data revealed a higher accumulation of endogenous ROS
in AMD-RPEs than Ctrl-RPEs as well as a more significantly
increased ROS production when additional treatment by H2O2
(Figure 4A). Several dietary supplements for retinal protection
and natural compounds for anti-oxidant, including β-carotene,
lutein, retinoic acid, forskolin, isoproterenol, resveratrol, vita-
min C, curcumin, and Q10, were selected in the present drug
screening study. To determine the safe dosage for each selected
candidate drug, the cell viability of AMD-RPEs after 24 h incu-
bation with the selected drugs at various concentrations was
measured by MTT assay (data not show). We selected the high-
est dosage that did not affect cell viability (with no cytotoxic
or proliferative effects) as the optimal treatment dose of each
drug (i.e., forskolin and lutein: 5μM; β-carotene, retinoic acid,
resveratrol, vitamin C, and curcumin: 10μM; Q10: 20μM; iso-
proterenol: 200μM). Among all of the above-mentioned can-
didate drugs, curcumin reduces the ROS production to a large
extent in AMD (Figure 4B). Based on these findings in the drug
screening study, we speculated that curcumin could be an effective
drug with therapeutic effects against oxidative stress in macular
degeneration.
EFFECT OF CURCUMIN ON H2O2-INDUCED CELL DEATH AND ROS
GENERATION
Ctrl- and AMD-RPEs were treated with curcumin at 0.1–200μM
for 24 h, and cell viability was determined by MTT assay. The
non-treated and lower concentrations curcumin-treated groups
(0.1, 1, and 10μM) showed no significant difference in cell viabil-
ity. We also found that curcumin at concentrations above 10μM
increased the proliferation of RPE cells. At higher concentrations
(150 and 200μM), curcumin decreased the viability of the cells
(Figure 5A). To determine the protective effects of curcumin on
H2O2-induced cell death, ctrl- and AMD-RPEs were pretreated
with 10μM curcumin at different time periods (0, 0.5, 1, 2, 4,
8, 12, 24, 36, and 48 h) prior to 200μM H2O2 exposure for 6 h.
MTT assay demonstrated that curcumin exhibited the protective
effect against H2O2-induced cell death when its pretreatment
time was less than 8∼12 h (Figure 5B). To exclude a direct
protective effect of curcumin, the cells were combined treatment
with 10μM plus 200μM H2O2 for 6 h. Our results showed that
the cell viability was not significantly different as compared to
the treatment with H2O2 alone, suggesting that curcumin had
no direct protective effects on the high dose H2O2-induced cell
death (Figure 5C). To evaluate the inhibitory effect of curcumin
on ROS production in ctrl- and AMD-RPE cells, we investigated
whether curcumin could inhibit H2O2-induced ROS production.
AMD- RPEs were pretreated with different concentrations (0.1,
1, and10μM) of curcumin for 12 h prior to 100μM H2O2
exposure for 6 h. As shown in Figure 5D, intracellular ROS was
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FIGURE 5 | Protective effect of curcumin on AMD-RPEs. (A) Cell viability in
AMD-RPEs treatment with different concentrations of curcumin for 24 h.
Each bar represents the mean ± SD of three independent experiments
(∗p < 0.05, compared with non-treated control). (B) Time effect of curcumin
on cells pretreated with 10μM curcumin at different time periods prior to
200μM H2O2 exposure for 6 h. Each bar represents the mean ± SD of three
independent experiments. (C) Cell viability was measured in AMD-RPEs
combine or 12 h pretreated with10μM curcumin or treated with 10μM
curcumin plus 200μM H2O2 for 6 h. Each bar represents the mean ± SD of
three independent experiments (∗p < 0.05, compared with vehicle control;
#p < 0.05. compared with non-treated control). (D) ROS production was
measured with flow cytometry for indicated conditions. RPEs were
pretreated with curcumin for 12 h and plus 100μM H2O2 for 6 h. Each bar
represents the mean ± SD of three independent experiments (∗p < 0.05,
compared with non-curcumin and non-H2O2treated control; #p < 0.05,
compared with non-curcumin but 100μM H2O2 treated group).
significantly increased by H2O2. Administration of curcumin
decreased and maintained intracellular ROS at low levels in
AMD-RPEs. These data suggest that curcumin effectively pre-
vented AMD-RPEs from H2O2-induced cell death and inhibited
ROS production in these RPE cells.
AMELIORATION OF OXIDATIVE STRESS IN THE AMD RPEs BY
CURCUMIN
Because the reduction of oxidative stress has been proposed to
be protecting against macular degeneration, we further tested
effects of therapeutic agents of curcumin, a naturally-occurring
compound with known anti-inflammatory and anti-oxidative
properties, in AMD iPSC-derived RPE. Curcumin significantly
attenuated this increase, indicating that curcumin acts as an
ROS scavenger in this system (Figure 5D). To understand the
molecular mechanism of curcumin-mediated protection of RPEs
against oxidative stress, we performed quantitative RT-PCR
to measure the expression of genes known to be involved in
cellular stress and inflammatory processes. AMD-RPEs exhibited
generally lower levels of antioxidant genes including HO-1, SOD2
and GPX1 when comparing with Ctrl-RPEs. After administration
of curcumin, the expression of these antioxidant genes was
significantly up-regulated (Figure 6A). Recent evidences have
demonstrated that curcumin may modulate growth factor
expression and can act as a therapeutic agent (Epstein et al., 2010;
Hollborn et al., 2013). PDGF, VEGF, and IGFBP-2 have been
shown to be involved in regular RPE functions or retinal diseases
(Epstein et al., 2010; Hollborn et al., 2013). We therefore wanted
to determine whether curcumin also regulated the expression of
PDGF, VEGF, and IGFBP-2. Quantitative RT-PCR showed that
AMD-RPEs express a higher level of these three factors when
compare with control, but supplementation of curcumin signif-
icantly reduced their expression (Figure 6B). In the next step, we
sought to determine whether H2O2 could change the secretion
of PDGF, VEGF, and IGFBP-2. To this end, we compared the
concentration of these three secretory proteins in the supernatant
of culture medium. Our results showed that the concentration
of soluble PDGF and VEGF were obviously increased after
treatment of H2O2 and significantly reduced by pretreated with
curcumin (Figures 6C,D). These data suggested that curcumin
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FIGURE 6 | Modulation of curcumin in oxidative stress-regulating genes.
qRT-PCR was used to quantify the relative amounts of (A) antioxidant genes
and (B) growth factors in the indicated groups. Each bar represents the
mean ± SD of three independent experiments (∗p < 0.01 compare with
vehicle control). Levels of platelet-derived growth factor (PDGF) and
(C) vascular endothelial growth factor (VEGF) (D) of AMD-RPEs in the
absence and presence of H2O2-stimulated and/or pre-treatment of curcumin.
Culture medium was assayed for enzyme-linked immunosorbent assay
(ELISA) as described in the methods section (∗p < 0.05). Data represents
three independent experiment and all data points plotted as mean ± SD
(∗p < 0.05). (E) Representative blots show comparative protein levels of total
and phosphor- JNK-1/2 in the AMD-RPEs.
might inhibit the H2O2-induced secretion of PDGF and VEGF.
It has been demonstrated that the JNK signaling pathway is
important in cell death. Thus, we determined the activity of the
JNK signaling pathway in H2O2-stimulated AMD-RPEs with or
without the pre-treatment of curcumin. As shown in Figure 6E,
western blotting data demonstrated that the phospho-JNK1/2
protein levels in the H2O2-stimulated AMD-RPEs pre-treated
with curcumin were significantly lower than those in the H2O2-
stimulated AMD-RPEs without curcumin pre-treatment, and
the total form JNK was not affected. Notably, adding PDGF-
neutralizing antibodies to medium consistently abrogated the
phosphorylation of JNK in H2O2-stimulated AMD-RPEs. Taken
together, our data suggested the pre-treatment with curcumin
could not only significantly increase oxidative stress defense
enzyme but also modulate secretion of PDGF and activity of
JNK pathway leading to inflammatory processes and cell death in
these oxidative-stress-damaged RPEs.
DISCUSSION
AMD is generally afflicts people over the age of 60-years-old,
and is the leading cause of vision loss among the elderly (Jager
et al., 2008; Eramudugolla et al., 2013). Risk factors of AMD
are various and include aging and different genetic predispo-
sitions, together with several environmental/epigenetic factors,
such as, cigarette smoking, dietary habits, and phototoxic expo-
sure (Nowak, 2006; Shahid et al., 2012; Stanton and Wright,
2014). To date, there is no specific therapy for curing AMD
or improving the visual functional on this progressive disease.
No effective agents could be screened until now due to a lack
of knowledge and materials about the disease pathogenesis of
AMD. This makes it necessary to create study models for study-
ing AMDpathogenesis and to design new therapeutic approaches.
Recently, patient-specific iPSCs and their differentiated progenies
have provided models for particular individualized disease phe-
notypes that can be used to understand disease mechanisms and
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FIGURE 7 | A schematic illustrations of interrelations between curcumin
and processes of AMD pathogenesis. AMD is a complex chronic
neurodegenerative disease associated with many environmental, lifestyle,
aging, and genetic factors. Oxidative stress and ROS production play a pivotal
role in AMD pathogenesis. Curcumin has remarkable efficacy in ameliorating
neurodegenerative, protecting AMD-RPEs from H2O2-induced ROS and cell
death, and the modulating several oxidative stress-regulating genes that may
inhibit cellular inflammatory responses and protects AMD-RPEs against
oxidative stress. These evidences indicated curcumin may be potentially
effective therapeutic means to treat AMD.
investigate the pathogenesis of disease-causing mutations (Singh
et al., 2013; Romano et al., 2014). In addition, the high consis-
tency, purity, and expandability of human iPSCs facilitate drug
screening, toxicity testing, and the development of personalized
medicine for the treatment of degenerative diseases (Saha and
Jaenisch, 2009). Nevertheless, iPSCs technology is complicated
because of genome-integrating viral vectors may produce inser-
tional mutations, or even result in increasing the risk of tumor
formation due to reactivation of the c-Myc oncogene (Stadtfeld
et al., 2008; Eggenschwiler and Cantz, 2009). Recently, the devel-
opment of non-viral, non-integrating, plasmid-based reprogram-
ming systems has gained popularity as an alternative to traditional
retroviral-based reprogramming of cells (Fusaki et al., 2009). In
this study, we generated patient-specific iPSC via integration-free
Episomal vectors iPSCs instead of integrating viral vectors. The
episomal vectors based on the Epstein-Barr Nuclear Antigen-1
(EBNA-1) have been proven to generate iPSCs very efficiently
without the risk of transgenic sequences inserted into the tar-
get cell genome. This method represents one step closer to the
clinical application of iPSC-based therapy of macular degener-
ation. Fibroblasts were commonly used in many studies for the
generation of iPSCs, it still suboptimal for large-scale clinical
derivation because of the need for invasive skin biopsies and the
cost long time for establishing stable cell lines from primary tissue
(Su et al., 2013). Reciprocally, mononuclear cells from peripheral
blood have been widely accepted as a more convenient and almost
unlimited resource for cell reprogramming due to the ease of
obtaining patient samples. Additionally, large numbers of frozen
blood samples, from living and deceased donors, are stored in
biorepositories worldwide (Haase et al., 2009; Loh et al., 2009).
We successfully isolated sufficient T cells from only 20ml periph-
eral blood of the donors and reprogrammed these T cells into
iPSCs. These iPSCs could be stably passaged to 50 passages and
retained their pluripotency and ability for tridermal differentia-
tion. Subsequently, we differentiated these iPSCs into RPEs and
demonstrated that these RPEs recapitulated multiple pathophysi-
ological features of macular degeneration. These features enabled
the use of these patient-specific RPEs as a high-throughput and
expandable platform for in vitro drug screening.
The generation of ROS has been considered to have harm-
ful consequences, and has been thought to be a major factor in
aging and disease (Handa, 2012). RPE cells are particularly sus-
ceptible to oxidative stress, high oxygen tension, lifelong light
illumination, and phagocytosis. Therefore, in accordance with
the decrease of antioxidative enzymes in RPE cells with age,
oxidative stress is thought to play a critical role in the patho-
genesis of macular degeneration (Beatty et al., 2000). There is
no effective drug or strategy to improve AMD debilitating visual
disease. Therefore, the elucidation of its underlying pathogenesis
and the development of novel therapies for macular degenera-
tion are urgently needed. Curcumin is widely used in traditional
Chinese medicine because of its multifaceted beneficial effects,
including anticancer, antioxidant, and neuroprotective properties
(Anand et al., 2007; Aggarwal and Harikumar, 2009). In addition,
curcumin has shown remarkable efficacy in ameliorating neu-
rodegenerative disorders (Aggarwal and Harikumar, 2009; Jiang
et al., 2013) and RPE cell death induced by light or oxidative
insults (Mandal et al., 2009; Woo et al., 2012). The efficacy of
curcumin has been attributed to the upregulation of oxidative
stress defense enzymes (Woo et al., 2012) and the activation of
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several cellular regulatory proteins that inhibit cellular inflamma-
tory responses and protection (Sreejayan and Rao, 1997; Mandal
et al., 2009; Woo et al., 2012). Among several dietary supple-
ments for retinal protection and natural antioxidant compounds,
we identified curcumin as a potent agent that can prevent AMD-
RPEs from H2O2-induced cell death and ROS production. In
addition, inflammation and angiogenesis have been implicated in
the pathogenesis of AMD. Production of cytokines and ROS leads
to further RPE and photoreceptor damage. Based on our data,
curcumin with its pleiotropic activities can modulate the expres-
sion of many oxidative stress regulatory proteins such as PDGF,
VEGF, IGFBP-2, HO1, SOD2, and GPX1, which in turn inhibit
cellular inflammatory responses and protect RPE cells. Although
the mechanisms of curcumin that improved RPE functions in
AMD-RPEs were not fully elucidated, our data indicated that, at
least in part, a potent ROS scavenging effect was involved in this
curcumin-mediated cytoprotection (Figure 7). The in vivo thera-
peutic potential of curcumin for the treatment of AMD should be
examined in animal models in future studies.
CONCLUSIONS
This report has demonstrated that patient-specific iPSCs and
iPSC-derived RPE-like cells are promising in vitro disease mod-
els for drug screening. In addition, curcumin may be an ideal
drug to effectively reduce ROS production, inhibit H2O2-induced
cell death and impair RPE functions. This intervention strategy
represents an ideal model in combination of iPSC-based per-
sonalized medicine and nanomedicine technologies. To sum, our
work shows that patient-specific iPSCs can act as an efficient
platform for drug screening and could help move personalized
medicine forward.
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